A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

This study is testing new combinations of cancer medications to see how well they work against advanced solid tumors that have a specific genetic change called a 'RAS mutation.' By combining these experimental drugs with immune-boosting therapy or standard chemotherapy, doctors hope to find more effective ways to stop tumor growth.

You may be eligible if you are 18 or older with advanced cancer that has a RAS mutation and has progressed after previous treatments, or if you have certain types of lung cancer that haven't been treated yet. You also need to be well enough to carry out daily activities on your own.

Participants will receive experimental medications, often combined with immunotherapy or chemotherapy, while doctors carefully monitor their health and the effects of the treatment. This involves regular clinic visits to track how your body responds to the medicine and to ensure your safety.

The study is currently recruiting patients at medical centers in Norwich, Connecticut; Nashville, Tennessee; and Houston, Texas. Because this is a clinical trial, you will have a dedicated team overseeing your care throughout the process.